$LVTX News
Last published 11mo ago
- 11mo agoLVTXXOMAXOMAOXOMAPXOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.GlobeNewswireEMERYVILLE, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) today announced it has successfully completed its previously announced acquisition of all the outstanding
- 12mo agoLVTXLAVA Announces Exceeding Minimum Condition in Tender Offer and Intent to Delist from NasdaqGlobeNewswireUTRECHT, The Netherlands, and PHILADELPHIA, Nov. 13, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ("LAVA") (NASDAQ:LVTX) today announced that 22,877,463 of LAVA's common shares, representing approximately 87% of
- 1y agoLVTXXOMALAVA Therapeutics N.V. Shareholders are Reminded to Tender Shares for XOMA Royalty Transaction Before November 12, 2025 DeadlineGlobeNewswireUTRECHT, The Netherlands and PHILADELPHIA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ("LAVA") (NASDAQ:LVTX) today announced a reminder to LAVA shareholders related to the proposed transaction with XOMA
- 1y agoLVTXXOMAXOMAOXOMAPXOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase AgreementGlobeNewswire- Amendment includes finalized cash amount and updated CVR terms for tender offer - LAVA announces new date for extraordinary general meeting of shareholders EMERYVILLE, Calif. and UTRECHT, The Netherlands and
- 1y agoLVTXXOMAXOMAOXOMAPXOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.GlobeNewswireEMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Oct. 02, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) and LAVA Therapeutics N.V. ("LAVA") (NASDAQ:LVTX) today
- 1y agoLVTXLAVA Therapeutics to Move Extraordinary General Meeting to Early November 2025GlobeNewswireAdditional time enables LAVA Therapeutics to address potential liabilities and confirm net cash to be delivered to Shareholders. LAVA Therapeutics and XOMA Royalty anticipate closing the announced acquisition in the
- 1y agoLVTXLAVA Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswireAnnounced entry into an agreement to be acquired by XOMA Royalty Corporation for between $1.16 and $1.24 per share in cash, plus a contingent value right related to LAVA's two partnered assets and unpartnered
- 1y agoLVTXXOMAXOMAOXOMAPXOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value RightGlobeNewswireEMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) and LAVA Therapeutics N.V. ("LAVA") (NASDAQ:LVTX) announced
- 1y agoLVTXLAVA Reports First Quarter 2025 Financial Results, Provides Business UpdateGlobeNewswireFocused on evaluation of strategic alternatives, with restructuring and closure of the Netherlands operationsEnrollment in LAVA-1266 Phase 1 continues to progressCash, cash equivalents and short-term investments of $66.6
- 1y agoLVTXLAVA Therapeutics Granted Full Waiver for RVO Payment ObligationGlobeNewswireExemption from the $5.1 million repayment obligation strengthens LAVA's balance sheet Underscores focus on cost curtailment and strategic option evaluation UTRECHT, The Netherlands and PHILADELPHIA, April 16, 2025
- 1y agoLVTXLAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business UpdateGlobeNewswireFocused on the evaluation of strategic alternativesAdopted a restructuring plan to extend capital resources, incurring a reduction in workforce of 30% to support the evaluation of strategic options and the Phase 1 study
- 1y agoLVTXLAVA Announces Evaluation of Strategic OptionsGlobeNewswireAdvisor engaged in evaluating strategic options to maximize shareholder value Cash balance of $76.6 million as of December 31, 2024 UTRECHT, The Netherlands and PHILADELPHIA, Feb. 25,
- 1y agoLVTXLAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological CancersGlobeNewswireLAVA-1266 is a potent and selective bispecific anti-CD123 Gammabody®First-in-human study enrolling adult patients with CD123-expressing AML or MDSInitial Phase 1 data read-out expected by year-end 2025 UTRECHT, The
- 1y agoLVTXLAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027GlobeNewswireReprioritized pipeline to focus on LAVA-1266, with continued support for partnered programs with Pfizer (PF-08046052) and Johnson and Johnson (JNJ-89853413) and plan to discontinue development of LAVA-1207Fourth quarter
- 2y agoLVTXLAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewswireUTRECHT, The Netherlands and PHILADELPHIA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX, "LAVA")), a clinical-stage immuno-oncology company focused on developing its proprietary
- 2y agoLVTXLAVA Reports Second Quarter 2024 Financial Results and Business UpdateGlobeNewswireContinued progress in Phase 1/2a dose escalation for LAVA-1207, including the monotherapy arm, now enrolling in dose level 12, and the pembrolizumab combinationFavorable safety profile for LAVA-1207Next data update for
- 2y agoLVTXLAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual ConferenceGlobeNewswireUTRECHT, The Netherlands and PHILADELPHIA, June 20, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX, "LAVA")), a clinical-stage immuno-oncology company focused on developing its proprietary
- 2y agoLVTXLAVA Announces Annual Meeting of ShareholdersGlobeNewswireUTRECHT, The Netherlands and PHILADELPHIA, June 10, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX, "LAVA")), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody®
- 2y agoLVTXLAVA Therapeutics to Participate in the Jefferies Global Healthcare ConferenceGlobeNewswireUTRECHT, The Netherlands and PHILADELPHIA, May 30, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX, "LAVA, " or "Company")), a clinical-stage immuno-oncology company focused on developing its proprietary
- 2y agoLVTXLAVA Provides Business Updates and Reports First Quarter 2024 Financial ResultsGlobeNewswireLAVA-1207 dose escalation progressing in Phase 1/2a trial in prostate cancer, with pembrolizumab combination expected to begin in Q2 2024Received $7.0 million clinical development milestone from Pfizer for PF-08046052
- 2y agoLVTXLAVA Therapeutics to Participate in the Citizens JMP Life Sciences ConferenceGlobeNewswireUTRECHT, The Netherlands and PHILADELPHIA, May 06, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX, "LAVA, " or "Company")), a clinical-stage immuno-oncology company focused on developing its proprietary
- 2y agoLVTXLAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial ResultsGlobeNewswireLAVA-1207 progressing in Phase 1/2a study, with pembrolizumab combination expected to begin in Q2 2024In March 2024, Pfizer paid LAVA $7 million for achieving a clinical milestone for EGFRd2 (PF-08046052/formerly
- 2y agoABBVLVTXMRKONCYIncreasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New TreatmentsGlobeNewswirePALM BEACH, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Pancreatic cancer is one of the leading causes of cancer death globally. The increasing incidence of this cancer across the U.S. and
- 2y agoLVTXLAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)GlobeNewswireUTRECHT, The Netherlands and PHILADELPHIA, March 05, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX, "LAVA")), a clinical-stage immuno-oncology company focused on developing its proprietary
- 2y agoLVTXLAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®GlobeNewswireCollaboration will support the initiation of a combination arm in the ongoing Phase 1/2a trial in patients with mCRPC Enrollment will continue in the monotherapy and IL-2 combination arms of the study UTRECHT, The
- 2y agoLVTXLava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial ResultsGlobeNewswireLAVA-1207 in mCRPC continues Phase 1/2a dose escalation study in monotherapy arm and in combination with IL-2Seagen initiated a Phase 1 study of SGN-EGFRd2 (LAVA-1223) to evaluate the safety and tolerability utilizing
- 3y agoLVTXLAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewswireUTRECHT, The Netherlands and PHILADELPHIA, Sept. 06, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of
- 3y agoLVTXLAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial ResultsGlobeNewswireSignificant progress with lead program LAVA-1207 in mCRPC reaching dose level 8Significant progress with collaborators including selection of lead candidate by Janssen Biotech and IND clearance for SGN-EGFRd2 (LAVA-1223)
- 3y agoLVTXLAVA Therapeutics to Participate in the H.C. Wainwright Immune Cell Engager Virtual ConferenceGlobeNewswireUTRECHT, The Netherlands and PHILADELPHIA , Aug. 14, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), an immuno-oncology company focused on developing its proprietary Gammabody® platform of
- 3y agoLVTXLAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash RunwayGlobeNewswire• LAVA-1207 for the treatment of prostate cancer will continue as the lead program• LAVA-051 Phase 1/2a clinical trial will be discontinued• Associated cost savings and initiatives are expected to extend the cash runway
- 3y agoLVTXLAVA Therapeutics Provides Business Update and Reports First Quarter 2023 Financial ResultsGlobeNewswireLead development candidate selected by Janssen Biotech under research collaboration provides a milestone payment to LAVAStrong balance sheet expected to provide cash runway into 2026 UTRECHT, The Netherlands and
- 3y agoLVTXLAVA Therapeutics Announces Selection by Janssen of Lead Gamma-Delta T-Cell Engager Bispecific Antibody to Move Toward Clinical DevelopmentGlobeNewswireThrough a research collaboration with Janssen, a lead candidate was identified for further development towards clinical studies.In May 2020, LAVA entered into a research collaboration and license agreement with Janssen
- 3y agoLVTXLAVA Therapeutics to Participate in the Jefferies Healthcare ConferenceGlobeNewswireUTRECHT, The Netherlands and PHILADELPHIA, June 01, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of
- 3y agoLVTXLAVA Announces Annual Meeting of ShareholdersGlobeNewswireUTRECHT, The Netherlands and PHILADELPHIA, May 30, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX) (LAVA), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™
- 3y agoLVTXLAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial ResultsGlobeNewswireInitial clinical data for LAVA-051 suggest a favorable safety profile and initial anti-tumor activity in the ongoing dose escalation Phase 1/2a clinical trial in patients with relapsed and refractory chronic lymphocytic
- 3y agoLVTXLAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of DirectorsGlobeNewswireUTRECHT, The Netherlands and PHILADELPHIA, March 09, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™
- 3y agoLVTXLAVA Therapeutics Announces Initial Data from the Ongoing Phase 1/2a Clinical Trial of LAVA-1207 in Therapy Refractory mCRPC at the 2023 ASCO GU SymposiumGlobeNewswireFavorable safety profile to date, with no occurrence of high-grade (>2) cytokine release syndrome or dose-limiting toxicitiesPreliminary signs of anti-tumor activity were observed, with iRECIST stable disease (iSD) in
- 3y agoLVTXLAVA Therapeutics to Present at the 2023 SVB Securities Global Biopharma ConferenceGlobeNewswireUTRECHT, The Netherlands and PHILADELPHIA, Feb. 09, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™
- 3y agoLVTXLAVA Therapeutics Announces the Appointment of Dr. Charles Morris as Chief Medical OfficerGlobeNewswireUTRECT, The Netherlands and PHILADELPHIA, Feb. 06, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of
- 3y agoLVTXLAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU SymposiumGlobeNewswireUTRECHT, The Netherlands and PHILADELPHIA, Jan. 23, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of
- 3y agoLVTXLAVA Therapeutics Announces Appointment of New Directors to the BoardGlobeNewswireUTRECHT, The Netherlands and PHILADELPHIA, Jan. 06, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™
- 3y agoLVTXLAVA Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceGlobeNewswireUTRECHT, The Netherlands and PHILADELPHIA, Jan. 03, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™
- 3y agoLVTXLAVA Therapeutics Announces Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and ExpositionGlobeNewswireUTRECHT, The Netherlands and PHILADELPHIA, Pa., Dec. 10, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™
- 3y agoLVTXLAVA Therapeutics Provides Business Update and Reports Third Quarter Financial ResultsGlobeNewswireLAVA-051 updated interim data from ongoing Phase 1/2a clinical trial in patients with relapsed or refractory chronic lymphocytic leukemia and multiple myeloma to be presented at 2022 American Society of Hematology (ASH)
- 4y agoLVTXLAVA Therapeutics to Present at the Jefferies London Healthcare ConferenceGlobeNewswireUTRECHT, The Netherlands and PHILADELPHIA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™
- 4y agoLVTXLAVA Therapeutics to Present Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and ExpositionGlobeNewswireUTRECHT, The Netherlands and PHILADELPHIA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™
- 4y agoLVTXLAVA Therapeutics Announces Appointment of Fred M. Powell as Chief Financial OfficerGlobeNewswireUTRECHT, The Netherlands and PHILADELPHIA, Nov. 01, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™
- 4y agoLVTXLAVA Therapeutics to Present On-Mechanism Pharmacodynamics Data from the Phase 1/2a Clinical Trial of LAVA-051 at the Society for Immunotherapy of Cancer (SITC) 2022 Annual MeetingGlobeNewswireUTRECHT, The Netherlands and PHILADELPHIA, Oct. 07, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™
- 4y agoPCGLVSWYNN9868-HK+16Stocks making the biggest moves midday: Wynn Resorts, Planet Fitness, AMC, Lyft and moreCNBCThese are the stocks posting the largest moves in midday trading.
- 4y agoLVTXSGENSeagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid TumorsGlobeNewswire– Seagen to Develop and Commercialize LAVA-1223, a Bispecific T Cell Engager Designed to Target and Activate Vγ9Vδ2 (Gamma Delta) T Cells in the Presence of EGFR-Expressing Solid Tumors – – LAVA to Receive Upfront Payment of $50 Million, With